Creating the crossroads
Through academia and industry, Gevorg Grigoryan PhD ’07 says there is no right path — just the path that works for you.
Through academia and industry, Gevorg Grigoryan PhD ’07 says there is no right path — just the path that works for you.
VEIR, founded by alumnus Tim Heidel, has developed technology that can move more power over long distances, with the same footprint as traditional lines.
Leuko, founded by a research team at MIT, is giving doctors a noninvasive way to monitor cancer patients’ health during chemotherapy — no blood tests needed.
Twelve finalists participated in initiative and 2023-24 MIT-Royalty Pharma Prize Competition, designed to support female biotech pioneers.
The startup Augmental allows users to operate phones and other devices using their tongue, mouth, and head gestures.
MIT spinout Boston Metal is commercializing a new method for making steel and other metals, to help clean up the emissions-intensive industry.
Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.
With laser-based precision tools for measuring and tuning materials, MIT spinout Optigon aims to rev up the energy transition.
Together, the Hasso Plattner Institute and MIT are working toward novel solutions to the world’s problems as part of the Designing for Sustainability research program.
The Trust Center executive director has penned a new book that gives entrepreneurs a sequence of actions to get their ventures out into the world.
The Institute’s “mind and hand” ethos has found a home in the United Arab Emirates.
MIT spinout 247Solar is building high-temperature concentrated solar power systems that use overnight thermal energy storage to provide power and heat.
The Engine Accelerator offers “tough tech” startups space, support, and a network to help them scale up.
For 10th consecutive year, the Institute ranks No. 2 among all colleges and No. 1 among colleges with one main campus, underlying the impact of innovation and critical role of technology transfer.
Immunai’s founders were researchers at MIT when they launched their company to help predict how patients will respond to new treatments.